Immunology

A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.

Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.

A literature review plus in-person visits helped identify barriers to quality rheumatoid arthritis care, as well as effective interventions to improve care quality.

A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.

Patients with axial spondyloarthritis who took part in exercise therapy showed improvements in disease activity and symptoms compared with patients who did not, a meta-analysis found.

Pain improvement was associated with remission or low disease activity in patients undergoing treatment for rheumatoid arthritis, a study found.

Patients with rheumatoid arthritis and obesity exhibited worse scores for subjective measures like pain and fatigue compared with those without obesity.

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.

Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.

Among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), intense pain symptoms were associated with poor sleep, fibromyalgia, depression, and sleep apnea.

A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.

Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.

Areas of focus in the annual report included health system utilization and recovery from the pandemic, patterns of medicine use, drug pricing, and patient out-of-pocket costs.

Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.

Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.

Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.

Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.

Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.

The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.